Carlayne E Jackson, M.D., FAAN

Carlayne E. Jackson, MD, FAAN, is currently professor of neurology and otolaryngology at the University of Texas Health Science Center San Antonio (UTHSCSA). She also serves as Chief of the Neuromuscular section and Vice Chair of Faculty Development and Wellness.  

Jackson is a graduate of Texas A&M University, where she received a bachelor's of science degree in Chemical Engineering. She obtained her medical degree at UTHSCSA, where she subsequently completed her neurology residency training and clinical neurophysiology fellowship. She has obtained board subspecialty certification in both clinical neurophysiology and neuromuscular medicine. She is a graduate of the Executive Leadership in Academic Medicine (ELAM) program sponsored by Drexel University College of Medicine. 

Jackson serves as medical director for the South Texas ALSA Center of Excellence and the MDA ALS Research Center. She is a member of the Western ALS Study Group, Northeast ALS Research Group, and the Muscle Study Group. She has participated in over 60 multi-center clinical trials in the areas of ALS, muscular dystrophy, and myasthenia gravis and has published over 240 abstracts, journal articles, and book chapters.  Jackson currently serves as Secretary for the American Academy of Neurology (AAN) Board of Directors and is Chair of the AAN Board Planning Committee and the AAN Meeting Management Committee.  She was awarded the AAN Leading in Excellence Mentorship Award in 2017.

• Professional Background

  Education

  • 1987 - MD - Medicine - UTHSCSA
  • 1983 - BS - Chemical Engineering - Texas A&M University

  Training

  • 1992 - Postdoctoral Fellowship - Neurophysiology - UTHSCSA
  • 1991 - Residency - Neurology - UTHSCSA
  • 1988 - Internship - Internal Medicine - UTHSCSA

  Highlights

  Texas Super Doctors
  Best Doctors in America
  Super Doctors Texas Hall of Fame

  Appointments

  • 6/2018 - Vice Chair for Faculty Development and Wellness - UT Health San Antonio, Neurology, San Antonio
  • 7/2007 - Professor w/Tenure - UTHSCSA, Otolaryngology/Head and Neck Surgery, San Antonio
  • 9/2006 - Professor w/Tenure - UTHSCSA, Neurology, San Antonio
  • 7/1991 - Staff Neurologist - Bexar County Hospital District, Medicine, San Antonio

• Instruction & Training

  • 9/2018 - Present, Neurology Consultative Service, The University of Texas Health Science Center
  • 09/2018 - present, Research - Peripheral Neuropathy, The University of Texas Health Science Center
  • 09/2002 - Present, Clinical Medicine - Occupational Therapy Clinical Series, ALS, The University of Texas Health Science Center
  • 09/1999 - Present, Research - ACES Neurology Lab, The University of Texas Health Science Center
  • 01/1996 - Present, Clinical Medicine - South Texas ALS Clinic, The University of Texas Health Science Center
  • 09/1994 - Clinical Medicine, Clinical Medicine - Attending Service, The University of Texas Health Science Center
  • 09/1991 - Present, Clinical Medicine - Consult Service, UHS
  • 09/1991 - Present, Clinical Medicine - Neurology Faculty Backup Call, The University of Texas Health Science Center
  • 09/1991 - Present, Clinical Medicine - Muscular Dystrophy Association, The University of Texas Health Science Center

• Research & Grants

  The majority of my research has centered on the participation in multi-centered clinical trials investigating potential novel therapies to slow disease progression in ALS. In addition to multi-center trials involving potential medical therapeutics, I have also been a leader in the investigation of respiratory interventions in the management of ALS. I have been extremely involved in the American Academy of Neurology and have served on committees to publish practice guidelines in the management of ALS and quality measures.

  Research profile

  Grants

  Ongoing Research Support:

  01/01/20-01/01/2023 Mitsubishi Tanabe Pharma Development America, Inc.
  A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS). Role: Principal Investigator

  01/01/2020-12/01/2022 Massachusetts General Hospital / HEALEY ALS PLATFORM TRIAL PLATFORM
  The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trialevaluating the safety and efficacy of investigational products for the treatment of ALS. Role:Co-Investigator

  07/01/2019-06/01/2022 University of Miami / Clinical Research In ALS - CAPTURE
  This is an observational natural history study of patients with ALS (or a related disorder) receiving care through the multi-disciplinary ALS clinics of participating CReATe Consortium centers. Role:Principal Investigator

  08/01/2017-08/01/2019 Cytokinetics, Inc.
  A Phase II, Multi-Center Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study To Evaluate The Efficacy, Safety, and Tolerability of CK-2127107 In Patients With Amyotrophic Lateral Sclerosis (ALS). Role: Site Principal Investigator

  09/01/2017-09/01/2019 Flex Pharma, Inc.
  A Randomized, Double-Blind, Controlled, Parallel Group Study To Evaluate The Efficacy and Safety of FLX-787-ODT For Treatment of Muscle Cramps In Adult Subjects With Motor Neuron Disease. Role:Co-Investigator

  02/01/2017-01/01/2018 Amylyx Pharmaceuticals, Inc.
  Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, A Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), For Treatment of Amyotrophic Lateral Sclerosis (ALS). Role: Site Principal Investigator

  01/01/2017-12/01/2018 Neuraltus Pharmaceuticals, Inc.
  A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 In Subjects With Amyotrophic Lateral Sclerosis (ALS).
  Role: Site Principal Investigator

  01/01/2017-12/01/2017 Cytokinetics, Inc.
  A Phase 3, Open-Label Extension Study of Tirasemtiv For Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031). Role: Site Principal Investigator

  10/01/2015-09/01/2016 Solstice Neurosciences, LLC
  A Phase III, Long Term, Open-Label and Single Arm Study of Myobloc In The Treatment of Troublesome Sialorrhea In Adult Subjects. To determine the efficacy of MYOBLOC® (as a single total dose of 2,500 Units or 3,500 Units) versus placebo in the treatment of troublesome sialorrhea in adult subjects to compare the safety and tolerability of MYOBLOC® versus placebo. Role: Site Principal Investigator

• Service

  Department

  Development of the South Texas ALS Clinic (Director) 01/1996-Present

  School

  UT Health Physicians Board of Directors (09/2009-04/2018)
  Review Committee of the Health Science Center‘s Faculty Promotions, Tenure, and Appointments Committee, UTHSCSA, School of Medicine, Dept. of Clinical Laboratory Science (10/2015-10/2016)

  Institutional

  PTAC Review Committee 01/2015-12/2016
  Executive Committee 03/2013-06/2016

• Publications

  ABSTRACTS:
  Shahid N, Jackson CE. Unknown Significance - I Think Not. Poster presentation at 42nd Annual Carrell-Krusen Neuromuscular Symposium Wolters Kluwer; 2020 Mar. (Clinical Neuromuscular Disease; vol. 21, no. 3).

  Hahid N, Donnelly J, Bhavaraju-Sanka R, Jackson CE. A Rare Case of Congenital Muscular Dystrophy. Poster presentation at the 42nd Annual Carrell-Krusen Neuromuscular Symposium Wolters Kluwer; 2020 Mar. (Clinical Neuromuscular Disease; vol. 21, no. 3).

  Jackson CE. Minimal Manifestation Status and Prednisone Withdrawal In The MGTX Trial 2019 Aug. (Muscle & Nerve; vol. 60, no. S1).

  PUBLICATIONS:
  Benatar M, Zhang L, Wang L, Granit V, Statland J, Baron R, Swenson, Ravits J, Jackson CE, Burns T, Trivedi J, Pioro E, Caress J, Katz J, McCauley J, Rademakers R, Malaspina A, Ostrow L, and Wuu, J, on behalf of the CReATe Consortium. Validation of Serum Neurofilament As Prognostic and Pharmacodynamic Biomarkers for ALS Neurology 2020 Jul;95(1)

  Rivner MH, Quarles BM, Pan J, Yu Z, Howard JF, Corse A, Dimachkie MM, Jackson CE, Vu T, Small G, Lisak RP, Belsh J, Lee I, Nowak RJ, Baute V, Scelsa S, Fernandes A, Simmons Z, Swenson A, Baron RJ, Sanka RB, Gooch C, Ubogu E, Caress J, Pasnoor M, Xu H, Mei L, LRP4 Research Group. Clinical Features of LRP4/Agrin Antibody Positive Myasthenia Gravis: A Multi-center Study Muscle & Nerve 2020 Jun

  Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, Lew M, Dashtipour K, Clinch T, Espay AJ, MYSTICOL Study Group. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults JAMA Neurology 2020 Apr;77(4):461-469.

  Andrews J, Jackson C, Heimann-Patterson T, Bettica P, Brooks BR, Pioro EP. Real-World Evidence of Riluzole Effectiveness In Treating Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2020 Mar

  Farhan S, Howrigan DP, Abbott LE, Byrnes AE, Churchhouse C, Phatnami H, Smith BN, Topp SD, Rampersaud E, Wu G, Wuu J, Gubitz A, Mordes DA, Ghosh S, CReATe Consortium, FALS Consortium, ALSGENS Consortium, Eggan K, Rademakers, McCauley JL, Schule R, Zuchner S, Benatar M, Taylor JP, Nalls M, Traynor B, Shaw CE, Golstein DB, Harms MB, Daly MJ and Neale BM. Exam Sequencing In Amyotrophic Lateral Sclerosis Implicates A Novel Gene, DNAJC7, Encoding A Heat-Shock Protein Nature Neuroscience 2019 Nov;22:1966-1974.

  Jackson CE, Heiman-Patterson T, Kittrell P, Baranovsky T, McAnanama G, Bower L, Agnese W, Martin M. Radical (Edaravone) For Amyotrophic Lateral Sclerosis: US Experience At 1 Year After Launch Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2019 Jul:605-610.

  Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki III A, Newsom-Davis J, Cutter GR, on behalf of the MGTX Study Group. Long-Term Effect Of Thymectomy In Patients With Non-Thymomatous Myasthenia Gravis Treated With Prednisone: 2-Year Extension Of The MGTX Randomised Trial The Lancet Neurology 2019 Mar;18(3):259-268.

  Jackson CE, De Carvalho M, Genge A, Heiman-Patterson T, Shefner JM, Wei J, Wolff AA. Relationships Between Slow Vital Capacity and Measures of Respiratory Function on the ALSFRS-R Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2018 Oct;19(7-8):506-512.

  Heiman Patterson T, Cudkowicz M, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews J, Chen D, Kulke S, Rudnicki S, Van Den Berg L. Understanding The Use of NIV In ALS: Results of An International ALS Specialist Survey Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2018 Aug;19(5-6):331-341.

• Clinical

  Provider profile

  Board Certifications

  • 2011 - Neurology with Added Qualifications in Neuromuscular Medicine - ABPN
  • 1993 - American Board of P&N/Neurology